Physician profile
Joseph B Schellenberg
NPI 1417929399
$1,963.67
in general payments reported to CMS, 2019-2025
25 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $115 · 2021: $111 · 2022: $350 · 2023: $681 · 2024: $133 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $244.07 | 2019-2023 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $228.83 | 2021-2023 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.65 | 2019-2023 | Ofev |
| Jazz Pharmaceuticals INC. | $145.04 | 2019-2023 | |
| Harmony Biosciences LLC | $141.17 | 2022-2023 | Wakix |
| Inspire Medical Systems, INC. | $132.53 | 2024 | Inspire |
| Lilly USA, LLC | $113.40 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $104.26 | 2021-2023 | Dupixent |
| Axsome Therapeutics, INC. | $93.22 | 2023 | Sunosi |
| Mylan Specialty L.P. | $78.22 | 2020-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $77.43 | 2019-2020 | |
| Genentech USA, INC. | $66.52 | 2020 | |
| Amgen INC. | $54.36 | 2022-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $44.51 | 2022-2023 | Aralast |
| United Therapeutics Corporation | $39.35 | 2022-2023 | Tyvaso |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.79 | 2019-2023 | |
| Philips North America LLC | $35.62 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $29.75 | 2019-2023 | Belsomra |
| Paratek Pharmaceuticals, INC. | $24.43 | 2023 | Nuzyra |
| Baxter Healthcare | $21.04 | 2023 | Hillrom - Life 2000 Ventilation System |
| Circassia INC. | $17.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.89 | 2019 | |
| Resmed Corp | $16.71 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schellenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.